Evotec SE today announced that EVT894, a monoclonal antibody to treat and potentially prevent chikungunya virus infections, has entered clinical development. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-starts-clinical-development-of-chikungunya-antibody-together-with-niaid-and-leading-academic-research-organisation-6020